



**Enhancement of  
Severe Combined Immunodeficiency (SCID)  
Newborn Screening  
Application for Funding Support**

---

Association of Public Health Laboratories

8515 GEORGIA AVENUE, SUITE 700 | SILVER SPRING, MD | 20910



**CONTENTS**

**INTRODUCTION** ..... 2

**SCORING CRITERIA** ..... 2

**TIMELINE** ..... 2

**ELIGIBILITY** ..... 2

**APPLICATION** ..... 3

**Section A: General Information** ..... 3

**Section B: Proposed Goals and Objectives** ..... 3

**Section C: Staffing Support** ..... 4

**Section D: Impact** ..... 4

**Section E: Budget and Budget Justification** ..... 4

**Section F: Sustainability Plan** ..... 4

**Section F: Additional Support** ..... 4

**Section G: Timeline** ..... 5

**QUESTIONS** ..... 5



**INTRODUCTION**

The Association of Public Health Laboratories (APHL) is pleased to continue our partnership with the Immune Deficiency Foundation (IDF) and RTI International to support screening and education programs for people with Severe Combined Immunodeficiency (SCID) through the [SCID Compass Program](#). Through this partnership, APHL will provide funding and technical assistance to NBS programs seeking support for implementation and/or enhancement of SCID newborn screening. This opportunity is available to all state NBS programs and NBS stakeholders.

**SCORING CRITERIA**

Applications will be evaluated based on the scoring criteria in the table below.

<b>Scoring Criteria and Points</b>	
Goals and Objectives	50 points
Staffing Support	5 points
Impact	10 points
Budget and Budget Justification	20 points
Sustainability Plan	10 points
Timeline	5 points
<b>Total Points Attainable</b>	<b>100 points</b>

**TIMELINE**

Applications are due by **Friday, October 30, 2020 at 11:59 pm ET**. Email the completed application to [Ruthanne.Sheller@aphl.org](mailto:Ruthanne.Sheller@aphl.org)

**Timeline**

- September 15, 2020 - Applications open
- October 30, 2020 - Applications due by 11:59 pm ET to APHL
- November 2-12, 2020 - Application review process
- November 13, 2020 - Awardees notified
- December 1, 2020 - Contracts ratified between APHL and awardees
- July 31, 2021 - Project completion date (or sooner)

Any modification to this anticipated schedule will be communicated on the website [www.aphl.org/rfp](http://www.aphl.org/rfp)

**ELIGIBILITY**

All U.S. and territorial NBS programs and NBS stakeholders are eligible to apply for this funding and are subject to the requirements to be set forth in a contract between APHL and the funded entity.



APHL will providing funding and technical assistance to NBS programs seeking support for implementation and/or enhancement of SCID newborn screening. Activities can include, but are not limited to, acquisition of instrumentation (molecular or next-generation sequencing), updates to existing equipment/materials and assays, multiplexing, technical assistance trainings, study designs and data collection efforts, updates to laboratory information management systems (LIMS), modifications to existing data exchange systems, expansion and strengthening of long-term follow-up and clinical referral networks, and other related activities in support of enhancing or improving your SCID newborn screening capabilities and capacities.

## **APPLICATION**

### **Section A: General Information**

NBS Program Name:

Address 1:

Address 2:

City:

State:

Zip Code:

Point of Contact:

Point of Contact Email:

### **Section B: Proposed Goals and Objectives**

Please describe:

- What you are hoping to accomplish with this funding?
- What barriers do you foresee and what are your plans to overcome them?
- What are your goals between now and the project end date (no later than July 31, 2021) to implement and/or enhance SCID newborn screening?
- What are the steps that are required to achieve these goals?
- What are the approximate start and completion dates (awarded funds must be spent by June 31, 2021)? Please be specific and detailed.
- Complete Goals Table, below. Please add or modify the table as suited to the needs of your project.



**Project Goals Table**

<b>Goal 1:</b>					
Goal 1	Activity	Outcome	Start Date	End Date	Staff lead
Step 1					
Step 2					
Step 3					
<b>Goal 2:</b>					
Goal 2	Activity	Outcome	Start Date	End Date	Staff lead
Step 1					
Step 2					
Step 3					

**Section C: Staffing Support**

Please describe:

- What staffing support do you currently have to meet the goals of this proposed project?

**Section D: Impact**

Please describe:

- What is the impact of this project on your NBS program and the mission of your SCID NBS activities?
- What metrics or tools will you use to track progress and impact?

**Section E: Budget and Budget Justification**

Please include a detailed budget and a budget justification for all expenses for which you are requesting funding. Itemize and justify all expenses (including personnel, equipment, supplies, and other expenses).

**Section F: Sustainability Plan**

Please respond to the following questions regarding sustainability:

- How will you sustain the project activities following the funding period?
- Please describe the steps involved to implement your sustainability plan, including the time required to implement the steps to achieve sustainability.

**Section F: Additional Support**

Please describe:

- What support do you need outside of financial support to implement the proposed NBS expansion solution (if any)?
- Are you currently receiving or have you previously received any funding to support SCID NBS activities (e.g. from APHL, the Centers for Disease Control and Prevention (CDC), etc.)?



### Section G: Timeline

Please provide a timeline of activities, with the project start date anticipated as December 1, 2020 and an end date of no later than July 31, 2021.

### QUESTIONS

If you have any questions about this funding opportunity, please contact Ruthanne Sheller at [Ruthanne.Sheller@aphl.org](mailto:Ruthanne.Sheller@aphl.org) or at 240.485.2767.

*This project is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling \$2.97 million with 0% percentage financed with nongovernmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS or the U.S. Government.*